Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome

A phase 2, randomized, double masked clinical, parallel-group clinical trial to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

Inclusion criteria

• Patients with diagnosis of mild-to-moderate drye eye syndrome.
• Male or female patients.
• Patients 18 years of age

Exclusion criteria

• Patients with one blind eye.
• Visual acuity of 20/40 in any eye
• Patients with history of active stage of any other concomitant ocular disease.
• Patients taking any medication, topically or by any other route, which could interfere with the study's results, in the 3 days prior to trial or until a time period in which residual effects could be present.
• Contraindications or sensitivity to any component of the study treatments.
• Ocular surgery within the past 3 months.
• Contact lens users.
• Females of childbearing potential )may not participate in the study if any of the following conditions exist:

• They are pregnant,
• They are breastfeeding,
• They have a positive urine pregnancy test at screening,
• They intend to become pregnant during the study, or
• They do not agree to use adequate birth control methods for the duration of the study.
• Participation in any studies of investigational drugs within 90 days previous to the inclusion.

Discontinuation criteria:

• Patients could be discontinued before the completion of the study because of adverse events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.